A PHASE I/II, OPEN-LABEL, SINGLE-ARM, STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH-4): PB2355